Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease

被引:115
作者
Spiegel, J
Hellwig, D
Möllers, MO
Behnke, S
Jost, W
Fassbender, K
Samnick, S
Dillmann, U
Becker, G
Kirsch, CM
机构
[1] Univ Saarland, Dept Neurol, D-66421 Homburg, Germany
[2] Univ Saarland, Dept Nucl Med, D-66421 Homburg, Germany
[3] Deutsch Klin Diagnost, Dept Neurol, D-6200 Wiesbaden, Germany
关键词
Parkinson's disease; transcranial sonography; FP-CIT SPECT;
D O I
10.1093/brain/awl042
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hyperechogenic signal of substantia nigra (SN) in transcranial sonography (TCS) and reduced striatal uptake in FP-CIT SPECT are common findings in idiopathic Parkinson's disease (PD). But so far it is unknown whether the extent of SN hyperechogenicity represents a correlate for the degeneration of presynaptic dopaminergic neurons in PD. We performed TCS and I-123-labelled N-(3-fluoropropyl)-2 ss-carbomethoxy-3 ss-(4-iodophenyl)nortropane ([I-123]FP-CIT) SPECT in 53 patients with PD. Striatal FP-CIT uptake was quantified by measuring the striatal/posterior lobe binding of [I-123]FP-CIT. SN echogenicity was quantified by planimetric measurement of the maximum extension of hyperechogenic signals. We found no correlation between striatal FP-CIT uptake and echogenicity of the SN, neither contralateral to the clinically more affected body side (r = +0.08, P = 0.57; Pearson's correlation) nor ipsilateral (r = +0.01; P = 0.92). Our data show that the extent of SN hyperechogenicity does not correlate with the degeneration of presynaptic dopaminergic nerve terminals. Obviously SN hyperechogenicity and degeneration of presynaptic dopaminergic nerve terminals exist independently from each other and may be based on different pathomechanisms.
引用
收藏
页码:1188 / 1193
页数:6
相关论文
共 31 条
[1]   Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound [J].
Behnke, S ;
Berg, D ;
Naumann, M ;
Becker, G .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (03) :423-425
[2]  
Benamer HTS, 2000, MOVEMENT DISORD, V15, P692, DOI 10.1002/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO
[3]  
2-V
[4]  
Benamer HTS, 2000, MOVEMENT DISORD, V15, P503, DOI 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO
[5]  
2-V
[6]   Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease [J].
Berg, D ;
Metz, B ;
Reiners, K ;
Naumann, M ;
Becker, G .
MOVEMENT DISORDERS, 2005, 20 (03) :383-385
[7]   Perspectives of B-mode transcranial ultrasound [J].
Berg, D ;
Becker, G .
NEUROIMAGE, 2002, 15 (03) :463-473
[8]   Echogenicity of the substantia nigra -: Association with increased iron content and marker for susceptibility to nigrostriatal injury [J].
Berg, D ;
Roggendorf, W ;
Schröder, U ;
Klein, R ;
Tatschner, T ;
Benz, P ;
Tucha, O ;
Preier, M ;
Lange, KW ;
Reiners, K ;
Gerlach, M ;
Becker, G .
ARCHIVES OF NEUROLOGY, 2002, 59 (06) :999-1005
[9]   Echogenicity of the substantia nigra in Parkinsons disease and its relation to clinical findings [J].
Berg, D ;
Siefker, C ;
Becker, G .
JOURNAL OF NEUROLOGY, 2001, 248 (08) :684-689
[10]   Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy [J].
Berg, D ;
Jabs, B ;
Merschdorf, U ;
Beckmann, H ;
Becker, G .
BIOLOGICAL PSYCHIATRY, 2001, 50 (06) :463-467